Posters

Conjunctival squamous cell carcinoma: a series of three cases

Poster Details

First Author: S.Mano PORTUGAL

Co Author(s):    P. Guerra   F. Teixeira   N. Ferreira   F. Caiado   W. Rodrigues        

Abstract Details

Purpose:

To report 3 cases of conjunctival squamous cell carcinoma (CSCC) to determine clinical characteristics of the tumor and to evaluate the safety and efficacy of topical mitomycin C (MMC) 0.04% as adjuvant treatment after tumor excision.

Setting:

Ophthalmology department, Hospital Santa Maria, Centro Hospitalar Lisboa Norte

Methods:

Retrospective case series of three patients with CSCC followed at Hospital Santa Maria during the year of 2016. In all cases, the tumor was managed by surgical resection using excisional biopsy with 2 mm of uninvolved conjunctival margin, if corneal involvement - limited superficial keratectomy without compromise Bowman's layer, and cryotherapy to the remaining conjunctival margins. After histopathology confirmation of CSCC, patients received topical MMC one drop four times daily. Patients underwent 2 months of treatment with one week off interval between each week of treatment.

Results:

Two patients were male, the mean age was 42 years, one presented with new conjunctival lesion and the others with recurrences of already excised lesions. The mean evolution time of the primary lesion was 17 months. The tumor prior to excision displayed a mean horizontal larger diameter of 9.3 mm located primarily in the temporal conjunctiva and in 2 patients involved the cornea. MMC caused temporary local irritation, conjunctival chemosis and diffuse punctate epithelial erosions that resolved with artificial tears, but no long-term intraocular or extraocular complications. There was no recurrence over a mean follow up of 6 months.

Conclusions:

Based on this small series, CSCC is a slow progressive tumor that seems to have a preference for temporal conjunctiva. It can manifest as chronic unilateral localized lesion or more diffuse conjunctivitis. Topical mitomycin C 0.04% appears to be a safe and effective adjuvant therapy for excised CSCC, with few side effects that were easily manageable.

Financial Disclosure:

NONE